Search research articles
Contact Us
Filters
Showing results (111-120 of 235) with videos related to
Page
of 24
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab
Michael Offin, Narek Shaverdian, Andreas Rimner, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Cancer Discovery
|
August 21, 2020
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang, Jia Luo, Song Wu, et al.
Cancer Cell
|
October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Cancer Cell
|
February 13, 2019
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
Michael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Cancer Cell
|
May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
The Lancet. Respiratory Medicine
|
March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Natasha B Leighl, Matthew D Hellmann, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Page
of 24
Search research articles
Search
Showing results (111-120 of 235) with videos related to
Sort By:
Page
of 24
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab
Michael Offin, Narek Shaverdian, Andreas Rimner, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Cancer Discovery
|
August 21, 2020
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang, Jia Luo, Song Wu, et al.
Cancer Cell
|
October 10, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Cancer Cell
|
February 13, 2019
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
Michael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Cancer Cell
|
May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
The Lancet. Respiratory Medicine
|
March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Natasha B Leighl, Matthew D Hellmann, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Page
of 24